FC-11 induced degradation of FAK via ubiquitin-proteasome
system.
(a) Chemical structure of FC-11. (b) FAK degradation at the indicated
dose of FC-11. (c) Quantitative analysis of FAK levels after FC-11
treatment. The cells were treated by FC-11 at the indicated doses
for 8 h in PA1 cells, and the data was collected from three independent
experiments. (d) Confirmation of CRBN-based mechanism in driving degradation
of FAK upon FC-11 treatment. PA1 cells were treated for 8 h with FC-11
(+, 1 nM; ++, 10 nM; +++ 100 nM) alone, or pomalidomide (10 μM)
or PF562271 (10 μM) alone, or combination of FC-11 with pomalidomide
or with PF562271. (e) Confirmation of proteasome-based mechanism in
driving degradation of FAK upon FC-11 treatment. PA1 cells were treated
for 8 h with FC-11 (+, 1 nM; ++, 10 nM; +++ 100 nM) alone, MG132 (5
μM) or carfilzomib (5 μM) alone, or a combination of FC-11
with MG132 or with carfizomib.